IceCure Medical Ltd - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
ICCM Nasdaq 3840 www.icecure-medical.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for IceCure Medical Ltd

When Will IceCure Medical Ltd (NASDAQ:ICCM) Turn A Profit? - Jan 15th, 2026 4:05 am
IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales - Jan 12th, 2026 6:30 am
IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer - Dec 17th, 2025 6:30 am
IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting - Dec 10th, 2025 6:30 am
IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes - Dec 5th, 2025 6:30 am
Icecure Medical Ltd (ICCM) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... - Nov 26th, 2025 6:00 pm
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 - Nov 19th, 2025 6:30 am
IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer - Nov 18th, 2025 6:30 am
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification - Nov 14th, 2025 2:30 pm
IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025 - Nov 12th, 2025 6:30 am
IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction - Nov 10th, 2025 6:30 am
Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates - Nov 6th, 2025 6:15 am
Acadia Healthcare (ACHC) Beats Q3 Earnings and Revenue Estimates - Nov 5th, 2025 5:00 pm
IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival - Nov 3rd, 2025 6:30 am
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances - Oct 13th, 2025 6:30 am
IceCure Medical to Attend the 2025 Maxim Growth Summit - Oct 9th, 2025 6:30 am
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care - Oct 3rd, 2025 10:28 am
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above - Oct 3rd, 2025 10:19 am
IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented - Sep 30th, 2025 6:30 am
IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented - Sep 22nd, 2025 6:30 am